MTOC-Inactivating Peptides Block Spindle Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-mitotic agents targeting the mitotic spindle are insufficient in structural and functional complexity, leading to limitations in effectively inhibiting cancer cell proliferation and drug resistance, necessitating agents that act upstream of existing therapies to block cancer cell access to mitotic recovery mechanisms.
Innovation Solution
The use of a synthetic peptide targeting the Kinesin-14 tail and a Kinesin-5 antagonist to block spindle formation by inhibiting microtubule nucleation at the microtubule-organizing center (MTOC), specifically by blocking the BimC domain of Kinesin-5, preventing Kinesin-5 from counteracting Kinesin-14's ability to inhibit MTOC nucleation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-mitotic agents targeting the mitotic spindle are used, then some anti-proliferative effect is achieved, but the structural and functional complexity is insufficient leading to drug resistance
Solution Approach 1:
The invention segments the anti-mitotic approach into two distinct components: Kinesin-14 tail peptides that block MTOC nucleation and Kinesin-5 antagonists that prevent counteraction. This segmentation allows each component to target specific molecular mechanisms, increasing functional complexity while maintaining reliable anti-proliferative effects and overcoming drug resistance.
2Reliability
If existing anti-MSP drugs are used, then mitotic spindle function is blocked, but cancer cells can access mitotic recovery mechanisms
Solution Approach 1:
The invention applies preliminary action by blocking MTOC nucleation upstream in the mitotic pathway before spindle formation occurs. The Kinesin-14 tail peptides prevent microtubule nucleation at the MTOC, and the Kinesin-5 antagonists ensure this block is maintained, thereby preventing cancer cells from accessing downstream mitotic recovery mechanisms that would otherwise be available after spindle formation.
3Reliability
If Kinesin-5 is active, then it counters Kinesin-14 block of MTOC nucleation, but this reduces anti-mitotic efficacy
Solution Approach 1:
The invention applies preliminary anti-action by introducing Kinesin-5 antagonists that preemptively block the BimC domain of Kinesin-5. This prevents Kinesin-5 from exerting its harmful counteraction against the Kinesin-14 induced MTOC nucleation block, thereby maintaining reliable growth inhibition and preventing mitotic recovery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively induces mitotic arrest and growth inhibition in cells by preventing spindle formation, thereby overcoming drug resistance and enhancing the efficacy of existing anti-cancer therapies.
Implementation Method 1
Kinesin-14 blocks microtubule nucleation
Implementation Method 2
a Kinesin-5 antagonist that blocks the BimC domain of Kinesin-5, preventing Kinesin-5 from countering the ability of Kinesin-14 to block MTOC nucleation
Data Source
AI summary
Disclosed herein is the identification of a new therapeutic target, an upstream target, the microtubule-organizing center (MTOC), for arresting mitosis and inhibiting cell growth and proliferation. Achieving mitotic arrest involves the interaction of two proteins with the γTuRC of the MTOC: Kinesin-14 or a Tail peptide of Kinesin-14 having the amino acid sequence of SEQ ID NO: 1 and an antagonist capable of disarming the function of the BimC domain of Kinesin-5. Methods and compositions for screening for Kinesin-5 BimC antagonists are also disclosed.